obstructive sleep apnea

Dec 24, 2024

Vertex Receives US FDA Approval for ALYFTREK: A Breakthrough CFTR Modulator for Cystic Fibrosis Vertex Pharmaceuticals Incorporated announced that the FDA had approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily triple combination CFTR modulator for the treatment of cystic fibrosis. ALYFTREK is...

Dec 26, 2023

ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer ImPact Biotech, a biotechnology company in its clinical stage dedicated to advancing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for various solid tumors, announced on December 20, 2023, that the U.S....

Sep 20, 2023

Sleep Aids Market: Examining Cutting-Edge Technologies and Scientific Breakthroughs Sleep can be burdensome when it disrupts daily routines, requires a significant time commitment, and is marred by sleep disorders or disturbances that affect overall well-being. In today's fast-paced world, where stress, anxiety,...

Aug 16, 2023

Snoring, a common sleep-related issue, can disrupt both the snorer's sleep and that of their partner or roommate. As per the estimate, about 90 million Americans suffer from snoring, either temporarily or semi-permanently, due to colds, allergies, or other factors. Snoring can have several implications, and it can ...

May 30, 2023

Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...

Jan 12, 2023

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

May 30, 2022

Obstructive Sleep Apnea (OSA) is a common, chronic, sleep-related breathing disorder characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to either complete or partial obstruction of the airway, resulting in apneas, hypopneas, or both. Obstructive Sleep Apnea causes day...

Mar 03, 2022

Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...

Mar 18, 2019

The concept of sleep as a passive movement of unconsciousness has long been ruled out. But this act of rejuvenation hasn't just been restricted to the phase of resting. Usually, sleepers undergo five stages of sleep consisting of both REM (Rapid Eye Movement) and N-REM (Non- Rapid Eye Movement), each lasting f...